Skip to main content

FDA Approvals

Payers' Guide, FDA Approvals

Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

FDA Approvals of Novel Brand-Name Prescription Drugs in 2018

Payers' Guide, FDA Approvals

Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Advanced Cutaneous Squamous-Cell Carcinoma

Payers' Guide, FDA Approvals

Xeljanz (Tofacitinib) Receives Expanded Indication, Becoming the First Oral JAK Inhibitor Approved for Ulcerative Colitis

FDA Approvals, Oncology Overview, Payers' Guide, Oncology

New Indications Approved by the FDA in 2018 for Oncology Drugs

Dalia Buffery, MA, ABD

Breast Cancer, FDA Approvals, In the News, Oncology

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Breast Cancer, FDA Approvals, In the News, Oncology

Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness

FDA Approvals, In the News, Lung Cancer, Oncology

FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

FDA Approvals, In the News

FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Page 25 of 53
Results 241 - 250 of 527